- Home
- SAR vs AUTL Comparison
SAR vs AUTL Comparison
Compare SAR & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SAR | AUTL |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.7M | 431.2M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | SAR | AUTL |
|---|---|---|
| Price | $22.85 | $1.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $23.75 | $8.50 |
| AVG Volume (30 Days) | 125.1K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 14.20% | N/A |
| EPS Growth | N/A | ★ 28.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $669.62 |
| Revenue Next Year | $0.39 | $79.78 |
| P/E Ratio | $9.44 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $21.10 | $1.11 |
| 52 Week High | $25.64 | $2.70 |
Technical Indicators
Market Signals| Indicator | SAR | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 42.47 | 48.91 |
| Support Level | $22.56 | $1.27 |
| Resistance Level | $23.33 | $1.74 |
| Average True Range (ATR) | 0.54 | 0.11 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 34.65 | 21.51 |
Price Performance
Historical ComparisonAbout SAR Saratoga Investment Corp New
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.